Figure 3 | Scientific Reports

Figure 3

From: New Labyrinth Microfluidic Device Detects Circulating Tumor Cells Expressing Cancer Stem Cell Marker and Circulating Tumor Microemboli in Hepatocellular Carcinoma

Figure 3

Identification and quantification of CD44 positive CTCs in HCC patients. (A) Representative image of CTCs and WBCs additionally stained with antibody against CD44. Scale bar represents 10 μm. (B) Number of CD44+ CTCs/mL in HCC patients grouped by TNM stage. TNM stage 0-I vs non-HCC: p = 0.1130 (ns); ***stage II-IV vs non-HCC: p = 0.0001; stage 0-I vs II-IV, p = 0.0765 (ns). (C) CD44+ CTC positivity rate in TNM stage. *non-HCC vs Stage 0-I: p = 0.0445; *** non-HCC vs Stage II-IV: p = 0.0001; *Stage 0-I vs II-IV: p = 0.0159. (D) CD44+ CTC positivity rate in BCLC stage. *non-HCC vs Stage 0-A: p = 0.0325; **non-HCC vs Stage B-C: p = 0.0033; Stage 0-A vs Stage B-C: p = 0.4913 (ns).

Back to article page